MALVERN, Pa.--(EON: Enhanced Online News)--Leading academic and industry researchers will convene at The Desmond in Malvern, PA from Oct 3-4, 2013 for a two-day conference on early stage developments in cancer vaccines and gene therapy.
“Recent advances in the understanding of cancer has the potential to significantly improve the range of available therapies, and ultimately, survival rates across many different indications in oncology”
The conference agenda covers focused topics, including advances in early stage clinical research, specifically, the emerging role of molecular profiling and targeted therapies in cancer treatments. Presentation topics also include manufacturing considerations and challenges for emerging technologies and delivery of biologics.
A roster of more than 20 industry and academic representatives features renowned leaders including:
- Jeffrey Ulmer, Global Head, External Research at Novartis: Technologies for New and Improved Vaccines
- Albert Wong, Director, Brain Tumor Research Laboratories at Stanford University Medical Center: EGF Receptor as a Major Target for Cancer Therapy
- Daniel Powell, Research Associate Professor at University of Pennsylvania: New Innovative Approaches to Adoptive T cell Therapy for Cancer
The full agenda can be accessed through the conference website.
“Recent advances in the understanding of cancer has the potential to significantly improve the range of available therapies, and ultimately, survival rates across many different indications in oncology,” said Justin Poley, event organizer.
“This event was designed to bring together a variety of thought leaders to present the latest research, technologies and clinical approaches to develop anti-cancer therapies. The timing is particularly important, considering the number of novel, yet promising advances currently taking place in targeted oncology therapies,” he added.
This event is expected to attract a diverse range of attendees, from investors and executive-level representatives to principle investigators, researchers and service providers interested in the development of cancer immunotherapies.
Registration fee is 999.00 for regular attendees, but the early bird rate of 840.00 was recently extended to September 13th.
Event sponsors include Aldevron, Bioject Medical Technologies, BioSpherix, Immunomic Therapeutics, Oncosec, Puresyn, VGXI, Waisman Biomanufacturing, Pennsylvania Bio, DNAvaccine.com, GeneTherapyNET.com and NatureGeneTherapy.com.